Q3 Earnings Estimate for HIMS Issued By KeyCorp

Hims & Hers Health, Inc. (NYSE:HIMS) – Research analysts at KeyCorp issued their Q3 2025 earnings estimates for shares of Hims & Hers Health in a report released on Monday, October 20th. KeyCorp analyst J. Patterson anticipates that the company will post earnings of $0.08 per share for the quarter. KeyCorp has a “Sector Weight” rating on the stock. The consensus estimate for Hims & Hers Health’s current full-year earnings is $0.29 per share. KeyCorp also issued estimates for Hims & Hers Health’s Q4 2025 earnings at $0.09 EPS, FY2025 earnings at $0.53 EPS, FY2026 earnings at $0.59 EPS and FY2027 earnings at $0.87 EPS.

Hims & Hers Health (NYSE:HIMS) last released its earnings results on Monday, August 4th. The company reported $0.17 earnings per share for the quarter, missing analysts’ consensus estimates of $0.18 by ($0.01). Hims & Hers Health had a return on equity of 26.26% and a net margin of 9.63%.The business had revenue of $544.83 million during the quarter, compared to analysts’ expectations of $550.06 million. During the same period in the prior year, the company earned $0.06 earnings per share. The firm’s quarterly revenue was up 72.6% compared to the same quarter last year. Hims & Hers Health has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS.

Several other equities analysts have also recently weighed in on HIMS. Weiss Ratings reiterated a “hold (c+)” rating on shares of Hims & Hers Health in a research note on Tuesday, October 14th. Wall Street Zen lowered shares of Hims & Hers Health from a “buy” rating to a “hold” rating in a report on Monday, July 28th. Needham & Company LLC reissued a “hold” rating on shares of Hims & Hers Health in a report on Tuesday, August 5th. Zacks Research lowered shares of Hims & Hers Health from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, August 19th. Finally, Canaccord Genuity Group reaffirmed a “buy” rating and set a $68.00 price objective on shares of Hims & Hers Health in a research note on Friday, September 12th. Two investment analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and three have assigned a Sell rating to the company. According to MarketBeat.com, Hims & Hers Health presently has a consensus rating of “Reduce” and an average price target of $38.92.

Hims & Hers Health Stock Down 3.9%

Shares of Hims & Hers Health stock opened at $47.45 on Wednesday. The company’s 50 day moving average is $51.05 and its 200 day moving average is $49.20. Hims & Hers Health has a twelve month low of $18.33 and a twelve month high of $72.98. The company has a quick ratio of 4.46, a current ratio of 4.98 and a debt-to-equity ratio of 1.72. The company has a market cap of $10.72 billion, a price-to-earnings ratio of 59.31, a price-to-earnings-growth ratio of 3.42 and a beta of 2.25.

Insider Activity at Hims & Hers Health

In related news, CFO Oluyemi Okupe sold 145,000 shares of the stock in a transaction that occurred on Monday, September 15th. The shares were sold at an average price of $55.35, for a total value of $8,025,750.00. Following the transaction, the chief financial officer owned 128,984 shares in the company, valued at approximately $7,139,264.40. This represents a 52.92% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Andrew Dudum sold 660,000 shares of the company’s stock in a transaction that occurred on Thursday, August 7th. The stock was sold at an average price of $50.58, for a total value of $33,382,800.00. Following the completion of the sale, the chief executive officer owned 2,214,769 shares in the company, valued at approximately $112,023,016.02. This represents a 22.96% decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 1,432,206 shares of company stock worth $74,248,448. 13.71% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Geode Capital Management LLC lifted its position in shares of Hims & Hers Health by 1.5% during the 2nd quarter. Geode Capital Management LLC now owns 4,746,081 shares of the company’s stock valued at $236,622,000 after buying an additional 71,593 shares in the last quarter. Invesco Ltd. lifted its holdings in Hims & Hers Health by 502.2% in the 2nd quarter. Invesco Ltd. now owns 2,552,405 shares of the company’s stock valued at $127,237,000 after purchasing an additional 2,128,587 shares in the last quarter. Northern Trust Corp raised its holdings in shares of Hims & Hers Health by 19.5% during the 1st quarter. Northern Trust Corp now owns 2,435,512 shares of the company’s stock worth $71,969,000 after acquiring an additional 397,310 shares during the period. Yong Rong HK Asset Management Ltd raised its holdings in shares of Hims & Hers Health by 41.2% during the 1st quarter. Yong Rong HK Asset Management Ltd now owns 2,400,000 shares of the company’s stock worth $70,920,000 after acquiring an additional 700,100 shares during the period. Finally, Nuveen LLC purchased a new position in shares of Hims & Hers Health during the 1st quarter worth $58,403,000. Hedge funds and other institutional investors own 63.52% of the company’s stock.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.